Innovent and Daiichi Sankyo Partner on VANFLYTA in China
SAN FRANCISCO, USA and SUZHOU, China, August 9, 2026 Innovent Biologics and Daiichi Sankyo have entered into an exclusive...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN FRANCISCO, USA and SUZHOU, China, August 9, 2026 Innovent Biologics and Daiichi Sankyo have entered into an exclusive...
SAN DIEGO and TOKYO, Oct. 1, 2025 — Kura Oncology and Kyowa Kirin have announced the first patient dosing...
